{"id":"W4383982286","doi":"10.3390/curroncol30070481","title":"Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Pfizer (Canada); McMaster University; Spinal Cord Injury BC; Queen Elizabeth II Health Sciences Centre; Wilfrid Laurier University; University of Ottawa; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; TransCanada (Canada)","funders":"Pfizer Canada; Pfizer","keywords":"Alectinib; Medicine; Discontinuation; ALK inhibitor; Anaplastic lymphoma kinase; Internal medicine; Quality of life (healthcare); Tyrosine-kinase inhibitor; Lung cancer; Population; Crizotinib; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008135863,0.0002479467,0.0005343059,0.0002719894,0.0007869214,0.0008884789,0.0003455123,0.0004172676,0.0004737243],"category_scores_gemma":[0.002105612,0.0001152188,0.000529426,0.0009202952,0.0004665982,0.0002939132,0.0002803331,0.0006040651,0.00008433135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008211157,"about_ca_system_score_gemma":0.003518928,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4202036,"about_ca_topic_score_gemma":0.5329711,"domain_scores_codex":[0.9996106,0.00007104236,0.00002834967,0.00005295582,0.000122303,0.0001148014],"domain_scores_gemma":[0.9985198,0.0002288173,0.0004214627,0.00004551224,0.0003741235,0.0004102396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002469495,0.00035975,0.9792646,0.00008389747,0.0001599021,0.0004002715,0.0004106615,0.0005205352,0.0004267892,0.00004507905,0.0006317137,0.01522736],"study_design_scores_gemma":[0.0002302809,0.001568487,0.994476,0.00005444951,0.0001341259,0.0005212788,0.0004288601,0.0008861194,0.0001585607,0.00002406498,0.001490496,0.00002725032],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976203,0.001185478,0.00002262383,0.0001487475,0.000003474039,0.00002461716,0.000426615,0.000001516283,0.0005667291],"genre_scores_gemma":[0.9986708,0.0005171619,0.00005253688,0.00008445262,0.000009004456,0.000007374793,0.0005905737,7.37126e-7,0.0000672466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5797964,"threshold_uncertainty_score":0.8355154,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06654338882178695,"score_gpt":0.4213874283401342,"score_spread":0.3548440395183472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}